A Health Technology Assessment agency should make a choice whether to review the evidence produced elsewhere or whether evidence is to be produced within the agency and then used to reach a decision. The small size of Cyprus with limited resources should be considered in order to draw the most appropriate conclusion, with regard to the evidence production by the newly established agency. This project analyzes at which point in time Cyprus makes the decision to integrate new high cost medicines into the Formulary of Hospital Drugs, in relation to the time of publication of decisions, taken by the Health Technology Assessment agencies in England and Wales, Scotland and Ireland, for the inclusion of the same medicines and for the same indication, in their national health systems. The review of evidence produced elsewhere would be feasible for Cyprus, as opposition to the production of evidence being undertaken by the new agency, in the case where the other agencies would have already produced evidence before the Cyprus Authority starts reviewing them.

Health Technology Assessment, Reviewing of Evidence, Cyprus